Antitumor electrochemotherapy: New advances in the clinical protocol

Cancer

Volumn 77, Issue 5, 1996, Pages 956-963

  Domenge, Christian ^a   Orlowski, Stéphane ^b   Luboinski, Bernard ^a   De Baere, Thierry ^a   Schwaab, Guy ^a   Belehradek Jr , Jean ^a   Mir, Lluis M ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b SBPM/DBCM   (France)

Author keywords

bleomycin; electropermeabilization; head and neck; permeation nodule; Phase I; squamous cell (epidermoid) carcinoma

Indexed keywords

BLEOMYCIN;

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG PENETRATION; ELECTROCHEMOTHERAPY; FEMALE; HEAD AND NECK CANCER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME;

ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; BLEOMYCIN; BREAST NEOPLASMS; CELL MEMBRANE PERMEABILITY; COMBINED MODALITY THERAPY; ELECTRODES; ELECTROPHYSIOLOGY; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; TRANSCUTANEOUS ELECTRIC NERVE STIMULATION;

EID: 0030047319     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19960301)77:5<956::AID-CNCR23>3.0.CO;2-1     Document Type: Article

References (19)

1. Neumann E, Sowers AE, Jordan CA. Electroporation and electrofusion in cell biology. New York: Plenum Press, 1989.
2. Mir LM, Banoun H, Paoletti C. Introduction of definite amounts of nonpermeant molecules into living cells after electropermeabilization: direct access to the cytosol. Exp Cell Res 1988;175:15-25.
3. Orlowski S, Mir LM. Cell electropermeabilization: a new tool for biochemical and pharmacological studies. Biochim Biophys Acta 1993;1154:51-63.
4. Orlowski S, Belehradek J Jr., Paoletti C, Mir LM. Transient electropermeabilization of cells in culture. Increase of the cytotoxicity of anticancer drugs. Biochem Pharmacol 1988;37:4727-33.
5. Poddevin B, Orlowski S, Belehradek J Jr., Mir LM. Very high cytotoxicity of bleomycin introduced into the cytosol of cells in culture. Biochem Pharmacol 1991;42(S):67-75.
6. Tounekti O, Pron G, Belehradek J Jr., Mir LM. Bleomycin, an apoptosis-mimetic drug that induces two types of cell death depending on the number of molecules internalized. Cancer Res 1993;53:5462-9.
7. Belehradek J Jr., Orlowski S, Ramirez LH, Pron G, Poddevin B, Mir LM. Electropermeabilization of cells in tissues assessed by the qualitative and quantitative electroloading of bleomycin. Biochim Biophys Acta 1994;1190:155-63.
8. Mir LM, Orlowski S, Belehradek J Jr., Paoletti C. Electrochemotherapy: potentiation of antitumour effect of bleomycin by local electric pulses. Eur J Cancer 1991;27:68-72.
9. Belehradek J Jr., Orlowski S, Poddevin B, Paoletti C, Mir LM. Electrochemotherapy of spontaneous mammary tumours in mice. Eur J Cancer 1991;27:73-6.
10. Mir LM, Orlowski S, Poddevin B, Belehradek J Jr. Electrochemotherapy tumor treatment is improved by interleukin-2 stimulation of the host's defenses. Eur Cytokine Netw 1992;3:331-4.
11. Salford LG, Persson BRR, Brun A, Ceberg CP, Kongstad PC, Mir LM. A new brain tumour therapy combining bleomycin with in vivo electropermeabilization. Biochem Biophys Res Commun 1993;194:938-43.
12. Heller R, Jaroszeski MJ, Leo-Messina J, Perrot R, Van Voorhis N, Reintgen D, et al. Treatment of B16 mouse melanoma with the combination of electropermeabilization and chemotherapy. Bioelectrochem Bioenerg 1995;36:83-7.
13. Yamaguchi O, Irisawa C, Baba K, Ogihara M, Yokota T, Shiraiwa Y. Potentiation of antitumor effect of bleomycin by local electric pulses in mouse bladder tumor. Tohoku J Exp Med 1994;172:291-3.
14. Sersa G, Cemazar M, Miklavcic D, Mir LM, Electrochemotherapy: variable antitumor effect on different tumor models. Bioelecrrochem Bioenerg 1994;35:23-7.
15. Mir LM, Roth C, Orlowski S, Belehradek J Jr., Fradelizi D, Paoletti C, et al. Potentiation of the antitumoral effect of electrochemotherapy by an immunotherapy with allogeneic cells producing interleukin-2. CR Acad Sci (Paris) Sér III 1992;314:539-44.
16. Mir LM, Roth C, Orlowski S, Quintin-Colonna F, Fradelizi D. Belehradek J Jr., et al. Systemic antitumor effects of electrochemotherapy combined with histoincompatible cells secreting interleukin-2. J Immunother 1995;17:30-8.
17. Belehradek M, Domenge C, Luboinski B, Orlowski S, Belehradek J Jr., Mir LM. Electrochemotherapy, a new antitumor treatment: first clinical phase I-II trial. Cancer 1993; 72:3694-700.
18. Tellez-Bernal E, Belehradek M, Recondo G, Cvitkovic E, Leridant AM, Vericel R, et al. Phase II study of cisplatin and continuous infusion 5-fluorouracil and bleomycin for recurrent and metastatic head and neck squamous cell carcinoma. Am J Clin Oncol 1990;13:452-4.
19. Recondo G, Armand JP, Tellez-Bemal E, Domenge C, Belehradek M, De Vathaire F, et al. Recurrent and/or metastatic head and neck squamous cell carcinoma: a clinical, univariate and multivariate analysis of response and survival with cisplatinbased chemotherapy. Laryngoscope 1991;101:494-501.